| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6189882 | Brachytherapy | 2013 | 6 Pages |
Abstract
This study is among the first to assess urethral dosimetry for patients treated with HDR-BT for vaginal cancer. Patients who received five fractions of higher than 5Â Gy/fraction to 0.1Â cm3 of urethra (estimated EQD2 of 85Â Gy) are at increased risk of severe urethral toxicity.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Malolan S. Rajagopalan, Neeta Kannan, Hayeon Kim, Christopher J. Houser, Sushil Beriwal,